Business
biOasis Engages FreeMind Group to Access Non-Dilutive Global Funding Opportunities
biOasis Engages FreeMind Group to Access Non-Dilutive Global Funding Opportunities.
About this update from Bioasis Technologies Inc.
[{"type":"text","content":"\nbiOasis Engages FreeMind Group to Access Non-Dilutive Global Funding Opportunities\n\nbiOasis Engages FreeMind Group to Access Non-Dilutive Global Funding Opportunities\n\nVANCOUVER, BC--(Marketwired - June 15, 2017) - biOasis Technologies Inc. (OTCQB: BIOAF) (TSX VENTURE: BTI) announced today it has engaged FreeMind Group to assist the Company pursue non-dilutive funding opportunities globally.The biOasis Transcend technology has been demonstrated to transport several different drug modalities (e.g., antibodies, enzymes, small molecules) across the blood-brain barrier (BBB) and into the central nervous system (CNS). The value in Transcend is the potential to turn non-brain-penetrant drugs into novel medical entities, to deliver them to the brain and to treat a range of disorders (e.g., oncology, lysosomal disorders and neurodegenerative diseases). Therefore, Transcend has the potential to treat more than one hundred identified brain and other CNS disorders. Non-dilutive funding is available for many of these disorders from multiple government and private sources. FreeMind Group has the expertise to identify these funding sources and to assist biOasis throughout the funding process, from the preparation and submission of funding applications to pre-award negotiations.\"As we advance our internal programs, it is important to continue to drive new scientific discoveries and understand which diseases the Transcend platform may best serve. To this end, Freemind is an important strategic addition to our armamentarium. Dr. Reinhard Gabathuler, chief scientist, biOasis, will manage this collaboration,\" said Dr. Mark Day, chief executive officer.\"FreeMind can play an important dual role for us, both protecting shareholder value and helping biOasis identify potential diseases and translational endpoints of interest,\" said Dr. Day. \"Much of the work we will conduct fits well within the mandate of many organizations that provide this type of non-dilutive funding. FreeMind has a strong track record and is highly regarded by academia, industry, and the funding organizations. This should provide biOasis with greater opportunities for success in the grant funding process.\" About FreeMindEstablished in 1999, FreeMind is the largest consulting group of its kind working with academics and industry alike. FreeMind assists in maximizing pote...